Vnitr Lek 2017, 63(9):580-588 | DOI: 10.36290/vnl.2017.116

Diagnosis and management of metastatic pheochromocytoma and paraganglioma

Ivana Jochmanová*, Ivica Lazúrová
I. interná klinika LF UPJŠ a UNLP, Košice, Slovenská republika

Pheochromocytoma (PHEO) and paraganglioma (PGL) are rare catecholamine-producing neuroendocrine tumors arising from adrenal medulla or extra-adrenal sympathetic and parasympathetic ganglia. Most of the PHEOs/PGLs are benign tumors, but metastatic disease is common, especially in patients with particular genetic background. Although PHEOs/PGLs were described more than a century ago, diagnosis and therapy of metastatic disease are still challenging. Advances in understanding molecular and metabolic changes associated with tumorigenesis lead us to identification of the background of these tumors. Novel information allowed for development of more precise diagnostic methods and molecular therapeutic targets identification, which will improve care of patients with metastatic PHEO/PGL.

Keywords: diagnostics; management; paraganglioma; pheochromocytoma; therapy

Received: July 28, 2017; Accepted: September 4, 2017; Published: September 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jochmanová I, Lazúrová I. Diagnosis and management of metastatic pheochromocytoma and paraganglioma. Vnitr Lek. 2017;63(9):580-588. doi: 10.36290/vnl.2017.116.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Eisenhofer G, Lenders JW, Siegert G et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 2012; 48(11): 1739-1749. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejca.2011.07.016>. Go to original source... Go to PubMed...
    2. McNeil AR, Blok BH, Koelmeyer TD et al. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000; 30(6): 648-652. Go to original source... Go to PubMed...
    3. Pacak K, Lenders JWM, Eisenhofer G. Pheochromocytoma. Diagnosis, Localization, and Treatment. Willey-Blackwell: Malden (MA) 2007. ISBN 978-1405149501. Go to original source...
    4. Lenders JW, Eisenhofer G, Mannelli M et al. Phaeochromocytoma. Lancet 2005; 366(9486): 665-675. Go to original source... Go to PubMed...
    5. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer 2014; 38(1): 7-41. Dostupné z DOI: <http://dx.doi.org/10.1016/j.currproblcancer.2014.01.001>. Go to original source... Go to PubMed...
    6. Zelinka T, Strauch B, Petrak O et al. Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. J Hypertens 2005; 23(11): 2033-2039. Go to original source... Go to PubMed...
    7. Adlan MA, Bondugulapati LN, Premawardhana LD. Glucose intolerance and diabetes mellitus in endocrine disorders - two case reports and a review. Curr Diabetes Rev 2010; 6(5): 266-273. Go to original source... Go to PubMed...
    8. Jochmanova I, Pacak K. Pheochromocytoma/Paraganglioma: Update on Diagnosis and Management. In: Levine AC (ed). Adrenal Disorders: Physiology, Pathophysiology and Treatment. Humana Press 2018: in press. ISBN 978-3319624693. Go to original source...
    9. Callender GG, Rich T, Lee JE et al. Pheochromocytoma. In: Yao JC, Hoff PM, Hoff AO (eds). Neuroendocrine tumors. Humana Press: New York (NY) 2011, 221-243. ISBN 978-1603279963. Go to original source...
    10. Brouwers FM, Lenders JW, Eisenhofer G et al. Pheochromocytoma as an endocrine emergency. Rev Endocr Metab Disord 2003; 4(2): 121-128. Go to original source... Go to PubMed...
    11. Eisenhofer G, Lenders JW, Pacak K. Biochemical diagnosis of pheochromocytoma. Front Horm Res 2004; 31: 76-106. Go to original source... Go to PubMed...
    12. Eisenhofer G. Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem 201; 60(12): 1486-1499. Dostupné z DOI: <http://dx.doi.org/10.1373/clinchem.2014.224832>. Go to original source... Go to PubMed...
    13. Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287(11): 1427-1434. Go to original source... Go to PubMed...
    14. Pacak K, Eisenhofer G, Ahlman H et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007; 3(2): 92-102. Go to original source... Go to PubMed...
    15. Eisenhofer G, Goldstein DS, Walther MM et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88(6): 2656-2666. Go to original source... Go to PubMed...
    16. Hodin R, Lubitz C, Phitayakorn R et al. Diagnosis and management of pheochromocytoma. Curr Probl Surg 2014; 51(4): 151-187. Dostupné z DOI: <http://dx.doi.org/10.1067/j.cpsurg.2013.12.001>. Go to original source... Go to PubMed...
    17. Eisenhofer G, Goldstein DS, Sullivan P et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005; 90(4): 2068-2075. Go to original source... Go to PubMed...
    18. Jochmanová I, Pacak K. Feochromocytóm a paraganglióm: klinicko-genetické aspekty. Interná medicína 2015; 15(2): 74-77.
    19. Eiden LE, Iacangelo A, Hsu CM et al. Chromogranin A synthesis and secretion in chromaffin cells. J Neurochem 1987; 49(1): 65-74. Go to original source... Go to PubMed...
    20. d'Herbomez M, Do Cao C, Vezzosi D et al. Chromogranin A assay in clinical practice. Ann Endocrinol (Paris) 2010; 71(4): 274-280. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ando.2010.04.004>. Go to original source... Go to PubMed...
    21. Nijhoff MF, Dekkers OM, Vleming LJ et al. ACTH-producing pheochromocytoma: clinical considerations and concise review of the literature. Eur J Intern Med 2009; 20(7): 682-685. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2009.08.002>. Go to original source... Go to PubMed...
    22. Lenders JW, Duh QY, Eisenhofer G et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99(6): 1915-1942. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014-1498>. Go to original source... Go to PubMed...
    23. Pacak K, Timmers HJLM, Eisenhofer G. Pheochromocytoma. In: Jameson JL, DeGroot LJ, De Kretser DM et al (eds). Endocrinology: Adult & pediatric. 2 voll. 7th ed. Elsevier/Saunders: Philadelphia (PA) 2016: 1902-1930. ISBN 978-0-323-18907-1. Go to original source...
    24. Plouin PF, Fitzgerald P, Rich T et al. Metastatic Pheochromocytoma and Paraganglioma: Focus on Therapeutics. Horm Metab Res 2012; 44(5): 390-399. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0031-1299707>. Go to original source... Go to PubMed...
    25. Lloyd RV, Osamura RY, Kloppel G (eds) et al. WHO Classification of Tumours of Endocrine Organs. 4th ed. Vol. 10. WHO/IARC Classification of Tumours. WHO Press 2017. ISBN 978-92-832-4493-6.
    26. Eisenhofer G, Bornstein SR, Brouwers FM et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004; 11(3): 423-436. Go to original source... Go to PubMed...
    27. McBrideJF, Atwell TD, Charboneau WJ et al. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol 2011; 22(9): 1263-1270. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jvir.2011.06.016>. Go to original source... Go to PubMed...
    28. Jochmanova I, Wolf KI, King KS et al. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol 2017; 143(8): 1421-1435. Dostupné z DOI: <http://dx.doi.org/10.1007/s00432-017-2397-3>. Go to original source... Go to PubMed...
    29. Carrasquillo JA, Pandit-Taskar N, Chen CC. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma. Semin Nucl Med 2016; 46(3): 203-214. Dostupné z DOI: <http://dx.doi.org/10.1053/j.semnuclmed.2016.01.011>. Go to original source... Go to PubMed...
    30. Jochmanova I, Pacak K. Pheochromoctyoma: The First Metabolic Endocrine Cancer. Clin Cancer Res 2016; 22(20): 5001-5011. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.